科室简介

  武汉大学中南医院血液内科成立于上世纪70年代，经过多年发展，现有三个病区，开放床位105张，层流病床14张，每年门诊诊疗15000余人次，治疗住院患者3000余人次。血液内科配备独立的血液病实验室，医疗技术力量雄厚、设备先进齐全。开展包括细胞形态学/病理学、免疫学、细胞遗传学、分子生物学等血液专科检查，具有造血干/祖细胞检测、采集、分离、冷冻能力。诊治范围包括各类贫血、出血性疾病、血液肿瘤（如白血病、淋巴瘤、骨髓瘤）等血液病。开展的特色诊疗技术，包括TMI精准放疗预处理的造血干细胞移植技术、脐血微移植、非血缘脐血干细胞移植、无血浆置换术、双重滤过血浆置换术等新技术新疗法，同时牵头或合作进行多项国家级白血病、多发性骨髓瘤和淋巴瘤等疾病的临床试验，与省内多家医院开展专科联盟技术协作，常年举办国家级继续教育培训班（白血病/骨髓瘤）及血细胞分离单采技术临床应用培训班，在国内享有一定的声誉。我科目前是国家临床重点专科建设项目（血液肿瘤内科）、国家疑难病诊治能力提升工程建设项目（血液肿瘤内科）、国家药物临床试验机构血液病学基地、中国住院医师规范化培训基地血液专业血液检验基地、中华骨髓库志愿者干细胞采集基地、血液成分分离与细胞治疗华中标准化操作培训基地、武汉大学血液病学博士后流动站、移植医学中心（干细胞移植）、脐带血干细胞移植诊疗中心、MDS/MPN诊疗中心及多发性骨髓瘤慢病管理中心。

经过几代人的努力，武汉大学中南医院血液内科已经形成了一支年龄结构、学历层次、职称结构较为合理的学科梯队。科室目前有医师21人，其中博士生导师2人，硕士生导师7人，9人有1年以上海外工作学习经历。科室承担医学本科生及硕士、博士研究生的理论授课和临床教学任务，拥有博士后流动站和博士、硕士学位授权点，已培养博士后6名，博士研究生12名。承担各类各级别科研基金多项，包括国家重点项目1项、国家自然科学基金11项，湖北省、武汉市、学校基金30余项，并承担国家级教学课题、MOOC教学项目多项。科室人员以第一/通讯作者身份在国内外学术期刊发表学术论文200余篇，主编与参编人民卫生出版社等专著多部，专利多项。我科多年来与全球包括美国、法国、加拿大及香港地区等多家著名医院的血液中心及科研机构建立了长期稳定的医疗合作关系，为新诊疗技术的开展提供了可靠保证。近年来，血液科科技实力突飞猛进，2021年中国医院科技量值STEM 全国血液专科排名22 名。

科室主任周芙玲教授长期从事血液病的研究，聚焦恶性血液肿瘤治疗中的难点问题，取得了国际领先的研究成果，突破传统化疗模式，提出的抗氧化途径治疗急性髓系白血病的理论具有较高原创性，并获批国际发明专利，已推广应用。受邀参加国内外学术会议报告50余次，科研成果在美国血液学会（ASH）和欧洲血液学会议（EHA）等国际血液学舞台展示。入围2020年全国血液病专家学术影响力百强。获得2020年武汉大学“医学腾飞计划”突出贡献奖，主持国家重点项目1项，国家自然科学基金项目4 项，省市级项目12项。近五年以第一作者或通讯作者发表高水平SCI论文80余篇，单篇最高影响因子41分，单篇最高被引102次。主编专著5部，获国家发明专利12项。

 

Department of Hematology, Zhongnan Hospital of Wuhan University

Department of Hematology at Zhongnan Hospital of Wuhan University was established in the 1970s. After decades of development, it now possesses three wards with 105 open beds and 14 laminar flow beds, treating over 15,000 outpatients, 3,000 inpatients. Department of Hematology is equipped with an independent hematology laboratory and has advanced medical technology and equipment. It can carry out various routine and special examinations, including cell morphology/pathology, immunology, cytogenetics, molecular biology, etc, with the ability to detect, collect, isolate and freeze hematopoietic stem/progenitor cells. The scope of diagnosis and treatment includes various hematological diseases such as anemia, bleeding diseases, and hematological malignancies (including leukemia, lymphoma, multiple myeloma, etc.). Recently, novel strategies such as TMI-based conditioning regimen HSCT, Cord blood cell micro-transplantation, Cord blood cell transplantation and Plasma-free plasmapheresis and Double filtration plasmapheresis (DFPP) have been carried out. Meanwhile, multiple clinical trials and technical cooperation of professional alliance with local hospitals have been undertaken, endowing the Department with a reputation in China. The Department is currently being granted as multiple centers: National Key Clinical Specialty Construction Project (Hematology and Oncology), National Construction Project for Improving the Diagnosis and Treatment of Intractable Diseases (hematology oncology), Hematology Base of National Drug Clinical Trial Institution, Standardized Training Base for Chinese Resident Physician in Hematology, Volunteer Stem Cell Collection Base of Chinese Marrow Donor Program, Standardized Operation Training Base of Blood Component Separation and Cell Therapy in Central China, Postdoctoral Station of Hematology of Wuhan University, Transplantation Medical Center (Stem Cell Transplantation) of Wuhan University, Umbilical Cord Blood Stem Cell Transplantation Center, Diagnosis and Treatment Center for MDS/MPN and Chronic Disease Management Center for Multiple Myeloma.

After several generations of efforts, the Department of Hematology in Zhongnan Hospital has formed a discipline echelon with reasonable age structure, educational level and professional title structure. There are currently 21 physicians and 9 technicians in the department, including 2 doctoral instructors, 12 of which with doctoral degrees and 9 with at least 1 year of overseas workstudy experience. The department also has 5 postdoctoral fellows, 10 doctoral students, and 15 master students receiving education in hematology. It undertakes theoretical teaching and clinical teaching for medical undergraduates, masters and doctoral students, while incubating post-doctoral mobile station and authorized points for doctoral and masters degrees. It also undertakes various scientific research funds at various levels, including 1 National Key Project, 11 National Natural Science Foundation, more than 30 funds from Hubei Province, Wuhan City, and Wuhan University, and a number of national-level teaching programs and MOOC teaching projects. Staff of the department have published more than 200 academic papers in domestic and foreign academic journals as first/corresponding authors, several monographs of Renwei Edition as editor-in-chiefco-editors, and obtained several patents. The department has established long-term and stable medical cooperation relations with blood centers and scientific research institutions of many famous hospitals in China and abroad, including the United States, France, Canada and Hong Kong, providing a reliable guarantee for the development of new diagnosis and treatment technologies. In recent years, the scientific research strength of the department has grown tremendously. In 2020, the department’s STEM ranking of Chinese hospitals in terms of scientific and technological value has risen to No.22 among the nation’s other hospitals.

Professor Fuling Zhou, chief and director of the Department of Hematology, has engaged in basic and clinical research on hematological diseases for decades. She is specialized in the research on the pathogenesis and therapeutic targets of acute myeloid leukemia (AML), and has achieved internationally-leading research results, where she originally proposed the antioxidant pathway for the treatment of AML, which has been approved as a national invention patent and widely applied. Professor Zhou, shortlisted in the 2020 National Top 100 Academic Influence of Hematology Experts, has been invited to present at domestic and foreign academic conferences for more than 50 times. Her scientific research results have also been presented internationally such as the American Society of Hematology (ASH) and the European Hematology Conference (EHA). Additionally, she serves as the review committee of the National Natural Science Foundation of China, and has been repeatedly honored, including the 2020 Wuhan University "Medical Take-off Plan" Outstanding Contribution Award. She presided 1 national key project, 4 National Natural Science Foundation projects, 12 provincial and municipal projects with approved funds of over 23 million yuan. In the past five years, she has published more than 80 high-level SCI papers as the firstcorresponding author with highest single SCI impact factor of 41 and highest single citation of 102 times. She has published 5 monographs as the editor-in-chief and acquired 12 national invention patents.

 

联系方式：

护士站：027-67813137

医生办：027-67812751

实验室：027-67813083

门    诊：027-67813071